/

PBLA

Panbela Therapeutics, Inc.Closed

0.003000+0.00 +200.00%USD

OTC Markets OTCPK · as of Oct 12, 16:00 ET · 15m delay

Open

0.0200

Prev close

0.001000

Day range

0.02000.0200

52-week range

0.0001002.50

Volume

1.01K4.48×

Mkt cap

14.56K

P/E ttm

—

Fwd P/E

-0.00

EPS ttm

-517.80

Div yield

0.00%

Earnings

—

From 52w high

−99.88%

Price Chart

Yahoo Finance · delayed

PBLAOct 12, 2026O 0.0030H 0.0030L 0.0030C 0.00300.0000 (0.00%)

SMA 500.0049
SMA 2000.0064

1Y change −72.97% since Oct 13, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

PBLA Panbela Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −72.97%
1 month: +2,900.00%
3 months: −72.97%
6 months: +1,400.00%
Year to date: +1,400.00%
1 year: −72.97%

Valuation & ownership

Market cap: 14.56K
Enterprise value: 1.68M
P/E (ttm): —
Forward P/E: -0.00
PEG ratio: —
Price / book: —
Price / sales (ttm): —
EV / EBITDA: —
EPS (ttm): -517.80
EPS (forward): -5.66
Beta (5y monthly): 29.95
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 4.85M
Float: 4.85M
Short % of float: 3.30%
Short ratio (days): 0.11
Held by insiders: 0.00%
Held by institutions: 0.00%
Avg volume (3m): 226
50-day average: 0.004634
200-day average: 0.006453
52-week change: −72.97%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 34.5
vs 50-day SMA: −38.20%
vs 200-day SMA: −53.13%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 65.38%
Realised vol (20d, ann.): 1947.7%
From 52-week high: −99.88%
From 52-week low: +2,900.00%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): —
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 0.00%
Operating margin: 0.00%
Profit margin: 0.00%

DES

About Panbela Therapeutics, Inc.

Yahoo Finance profile

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Sector: Healthcare
Industry: Biotechnology
Employees: 7
Headquarters: Waconia, MN, United States
Website: panbela.com
Officers: Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D. CEO, President & Director
Ms. Susan Horvath VP of Finance, CFO, Secretary & Treasurer
Ms. Tammy Groene Vice President of Operations

SEAS

Seasonality · PBLA

2014–2026 · monthly returns

Strongest month Oct +69.06%Weakest month Aug −16.01%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	3150.0	669.2	-99.6	5450.0	-0.9	-54.5	122.0	-99.1	11000.0	-73.0			+1400.0%
2025	-7.9	4.6	-9.9	-19.6	-2.6	-10.1	-26.7	-7.1	-68.3	-60.0	-44.5	-98.2	−99.9%
2024	-92.4	-15.1	-43.2	-35.8	-7.0	0.0	-24.9	24.8	-5.2	3.4	-12.1	17.6	−97.9%
2023	-44.1	-16.5	-67.7	24.2	-59.0	-65.9	-12.6	-30.8	-5.8	-37.6	-35.2	72.6	−99.0%
2022	23.1	-8.5	8.2	-16.1	-15.3	-56.0	87.9	-44.3	-60.9	-53.2	7.0	-45.9	−95.8%
2021	56.2	-21.6	-9.4	16.7	-8.9	-32.6	-11.0	-9.9	-4.4	-1.4	-13.6	-6.5	−51.4%
2020	23.8	-7.7	9.4	0.0	-1.0	-4.2	26.5	-51.0	-2.6	-3.3	18.2	3.5	−15.2%
2019	14.3	-18.7	-15.4	-4.0	-5.3	-10.0	122.2	5.0	-4.8	16.4	-26.3	-2.1	+20.0%
2018	-17.8	-1.5	-25.9	-4.2	21.7	-3.6	-32.6	-22.0	12.7	0.0	0.0	-12.5	−65.0%
2017	-48.3	177.8	19.2	-28.4	-33.0	18.9	-32.4	-40.9	47.1	22.0	16.8	-29.8	−42.5%
2016	-22.9	0.0	-25.9	-2.5	15.4	-11.1	-23.6	0.0	-1.9	16.7	-48.6	-3.3	−75.1%
2015	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	856.7	17.4	3.9	+1066.7%
2014													—

PBLA

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

PBLA

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Panbela Therapeutics, Inc.

Seasonality · PBLA

Insider Activity · PBLA

Congress Trades · PBLA

Investors Holding PBLA

Investors Holding PBLA

Congress Trades · PBLA

Insider Activity · PBLA

Seasonality · PBLA

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Panbela Therapeutics, Inc.

Earnings & Dividends

News